The estimated Net Worth of Gerard J Michel is at least 3.27 百万$ dollars as of 8 December 2023. Mr Michel owns over 34,000 units of Delcath Systems stock worth over 2,612,956$ and over the last 10 years he sold DCTH stock worth over 520,755$. In addition, he makes 132,000$ as CEO & Director at Delcath Systems.
Mr has made over 26 trades of the Delcath Systems stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 34,000 units of DCTH stock worth 99,960$ on 8 December 2023.
The largest trade he's ever made was exercising 112,481 units of Delcath Systems stock on 3 August 2018 worth over 400,432$. On average, Mr trades about 15,426 units every 47 days since 2015. As of 8 December 2023 he still owns at least 262,345 units of Delcath Systems stock.
You can see the complete history of Mr Michel stock trades at the bottom of the page.
Gerard J. Michel is the CEO & Director at Delcath Systems.
As the CEO & Director of Delcath Systems, the total compensation of Mr Michel at Delcath Systems is 132,000$. There are 2 executives at Delcath Systems getting paid more, with John Purpura having the highest compensation of 682,541$.
Mr Michel is 58, he's been the CEO & Director of Delcath Systems since . There are 4 older and 5 younger executives at Delcath Systems. The oldest executive at Delcath Systems, Inc. is Roger Stoll, 78, who is the Non-Executive Independent Chairman of the Board.
Gerard's mailing address filed with the SEC is C/O DELCATH SYSTEMS, INC., 566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804.
Over the last 5 years, insiders at Delcath Systems have traded over 0$ worth of Delcath Systems stock and bought 1,192,084 units worth 8,856,388$ . The most active insiders traders include Marco Taglietti、Gerard J Michel、Advisors, Inc. Rosalind. On average, Delcath Systems executives and independent directors trade stock every 25 days with the average trade being worth of 242,307$. The most recent stock trade was executed by Gil Aharon on 19 March 2024, trading 26,882 units of DCTH stock currently worth 100,001$.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Delcath Systems executives and other stock owners filed with the SEC include: